John Bridgewater leads the clinical trials portfolio of the National Cancer Research Institute (NCRI) Hepatobiliary group (ABC-02 paper NEJM1, New EPOC paper Lancet Oncology2). He founded the International Biliary Tract Cancer Collaborators group and leads the NCRI Genomics England programme for upper gastrointestinal cancers.

He is working on a series of multidisciplinary studies including a study with Henning Walczak (UCL CI) using multiple immune phenotype measurements to guide personalised, sequential immunotherapy in a phase 1 programme. Patients with a poor response to PD-1 inhibition will be treated with a tailored, novel combination of immunotherapies, the immune response to which will in turn be measured. Therapy will adapt dependent on longitudinal immunoprofile.